French scientists identify possible new target for obesity treatment

French researchers have identified a protein that influences the body's sensitivity to leptin, the hormone that controls our body weight by letting us know when we have had enough to eat. The work, which is published online by the journal the Proceedings of the National Academy of Sciences (PNAS), could lead to the development of new treatments for obesity.

Leptin plays a key role in maintaining a healthy body weight by regulating food intake and energy expenditure. It works by triggering specific leptin receptors (OB-R) in the hypothalamic arcuate nucleus (ARC), the part of our brain responsible for controlling body weight.

The hormone is secreted by fat cells, and the level of leptin in the blood is proportional to the amount of fatty tissue in our bodies. In subjects with a healthy weight, high levels of leptin trigger an increase in energy expenditure and a decrease in appetite. This leads in turn to a decrease in the amount of fatty tissue and the amount of leptin circulating in the blood. However, in overweight and obese people, this system breaks down as the body becomes resistant to leptin, leading to further weight gain.

In 1997, scientists discovered that the gene which codes for the leptin receptor (OB-R) also codes for another protein, which they called OB-RGRP (OB-R gene related protein).

In this latest study, French scientists fed a high-fat diet to mice in which the production of OB-RGRP had been blocked. In spite of their unhealthy diet, the mice maintained a healthy body weight. The researchers found that OB-RGRP is responsible for the intercellular transport of the leptin receptor OB-R. Blocking the production of OB-RGRP led to an increase in the number of leptin receptors present on the cell surface, effectively rendering the cell more sensitive to leptin.

The scientists believe that inhibiting the production of OB-RGRP could restore the leptin-sensitivity of obese people and so help them to lose weight more easily.

"Our study provides interesting insights on regulatory mechanisms of BO-R signalling and shows that OB-RGRP is a promising therapeutic target for the treatment of obesity," the researchers write.

For more information, please visit:

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...